Generate:Biomedicines is working on generative biology: a novel approach to drug development that allows the company to program protein-based modalities for the first time by bringing together machine learning, automated experimentation, and cutting-edge science, will change the way biotherapeutics are developed.
As of 6/30/2025 Generate:Biomedicines represents 1.12% of the ARK Venture Fund. To see the most updated holdings and other fund information, please click here. Holdings subject to change.
ARK’s statements are not an endorsement of any company or a recommendation to buy, sell or hold any security. ARK and its clients as well as its related persons may (but do not necessarily) have financial interests in securities or issuers that are discussed. Certain of the statements contained may be statements of future expectations and other forward-looking statements that are based on ARK’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements.